Clinical Trials
47 trialsMechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
Peking University People's Hospital
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
USZ-STRIKE
ETOP IBCSG Partners Foundation
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
NovoCure Ltd.
Priming Immunotherapy in Advanced Disease With Radiation
University of Kentucky
SARCO-CTI
Ankara Etlik City Hospital
Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer
Anhui Provincial Hospital
Dupilumab_Metastatic NSCLC
Icahn School of Medicine at Mount Sinai
A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
PRIMM
University Medical Centre Maribor
Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant Immunotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
ImmuneSensor Therapeutics Inc.
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
BioAtla, Inc.
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
The First Affiliated Hospital of Zhengzhou University
An Observational Clinical Study of Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer With Stable Disease After PD-1 Inhibitor Treatment
Xinqiao Hospital of Chongqing
Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
PROPHET
Sun Yat-sen University
Analysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung Cancer
Shanghai Chest Hospital
NMN
Sichuan University
CLASSIC5
Hunan Province Tumor Hospital
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
BioAtla, Inc.
Impact of Concomitant Use of Steroids and Immune-Checkpoint Inhibitors on Survival Outcomes in NSCLC Patients
Seoul National University
Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer
Shanghai Chest Hospital
ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI
Peking Union Medical College Hospital
ATPase
Hunan Province Tumor Hospital
JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
CONFIRM
Hunan Province Tumor Hospital
CREATE
Hunan Province Tumor Hospital
CHEERS
University Hospital, Ghent
Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure
The Central Hospital of Lishui City
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
Fred Hutchinson Cancer Center
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain Metastases
Xiangya Hospital of Central South University
Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
Second Affiliated Hospital of Soochow University
SBRT Combined With PD-1 Inhibitor and Thoracic Hyperthermia for Advanced NSCLC
First People's Hospital of Hangzhou
Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
PARADIGM
VastBiome
Neoadjuvant Immunotherapy With Chemotherapy for Stage I-IIIB Non-Small Cell Lung Cancer Patients
Peking Union Medical College
Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer
Tongji Hospital
Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLC
Peking University Cancer Hospital & Institute
Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy
Fujian Cancer Hospital
Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC
Tianjin Medical University Cancer Institute and Hospital
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Sungkyunkwan University
Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors
Shanghai Pulmonary Hospital, Shanghai, China